TY - JOUR
T1 - Loci of catabolism of β-very low density lipoprotein in vivo delineated with a residualizing label, 125I-dilactitol tyramine
AU - Daugherty, A.
AU - Thorpe, S. R.
AU - Lange, L. G.
AU - Sobel, B. E.
AU - Schonfeld, G.
N1 - Copyright:
Copyright 2012 Elsevier B.V., All rights reserved.
PY - 1985
Y1 - 1985
N2 - β-Very low density lipoprotein (β-VLDL) may be a major atherogenic lipoprotein, and knowledge of the sites of its catabolism should facilitate elucidation of mechanisms important in the regulation of its plasma concentrations. In this study, catabolic sites of β-VLDL have been delineated in normolipidemic rabbits with a novel, radioiodinated, residualizing label, 125I-dilactitol tyramine (125I-DLT). Comparative studies of β-VLDL and low density lipoprotein catabolism were performed with 125I-DLT conjugated to each lipoprotein and with lipoproteins iodine-labeled conventionally. Conjugation did not alter size distributions or charge characteristics of lipoprotein particles. The overall processing (binding and degradation) of lipoproteins by cultured rabbit skin fibroblasts was not influenced by 125I-DLT derivatization, suggesting that attachment of the label did not influence cell receptor-lipoprotein interactions. Furthermore, although degradation products of 125I-lipoproteins leaked out of the cells and into the medium, the degradation products of 125I-DLT lipoproteins were retained by the cells. The principal catabolic site of β-VLDL in normolipidemic rabbits was found to be the liver with 54 ± 4% of injected 125I retained in this organ 24 h after injection of 125I-DLT-β-VLDL. When catabolism was normalized to tissue weight, the liver and adrenals were found to be approximately equally active in the metabolism of β-VLDL. In agreement with results of other studies with residualizing labels, the principal organ of catabolism of 125I-DLT-LDL in vivo was the liver. The adrenals were the most highly catabolizing organ when results were normalized for tissue weight. The quantitative differences observed in the tissue distributions of injected 125I-DLT-β-VLDL and 125I-DLT-low density lipoprotein suggested that a significant proportion of β-VLDL is removed by tissues before conversion to low density lipoprotein.
AB - β-Very low density lipoprotein (β-VLDL) may be a major atherogenic lipoprotein, and knowledge of the sites of its catabolism should facilitate elucidation of mechanisms important in the regulation of its plasma concentrations. In this study, catabolic sites of β-VLDL have been delineated in normolipidemic rabbits with a novel, radioiodinated, residualizing label, 125I-dilactitol tyramine (125I-DLT). Comparative studies of β-VLDL and low density lipoprotein catabolism were performed with 125I-DLT conjugated to each lipoprotein and with lipoproteins iodine-labeled conventionally. Conjugation did not alter size distributions or charge characteristics of lipoprotein particles. The overall processing (binding and degradation) of lipoproteins by cultured rabbit skin fibroblasts was not influenced by 125I-DLT derivatization, suggesting that attachment of the label did not influence cell receptor-lipoprotein interactions. Furthermore, although degradation products of 125I-lipoproteins leaked out of the cells and into the medium, the degradation products of 125I-DLT lipoproteins were retained by the cells. The principal catabolic site of β-VLDL in normolipidemic rabbits was found to be the liver with 54 ± 4% of injected 125I retained in this organ 24 h after injection of 125I-DLT-β-VLDL. When catabolism was normalized to tissue weight, the liver and adrenals were found to be approximately equally active in the metabolism of β-VLDL. In agreement with results of other studies with residualizing labels, the principal organ of catabolism of 125I-DLT-LDL in vivo was the liver. The adrenals were the most highly catabolizing organ when results were normalized for tissue weight. The quantitative differences observed in the tissue distributions of injected 125I-DLT-β-VLDL and 125I-DLT-low density lipoprotein suggested that a significant proportion of β-VLDL is removed by tissues before conversion to low density lipoprotein.
UR - http://www.scopus.com/inward/record.url?scp=0022406616&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022406616&partnerID=8YFLogxK
M3 - Article
C2 - 4055790
AN - SCOPUS:0022406616
SN - 0021-9258
VL - 260
SP - 14564
EP - 14570
JO - Journal of Biological Chemistry
JF - Journal of Biological Chemistry
IS - 27
ER -